Skip to main content
December 08

December 08, 2021
Bad Homburg, Germany

Credit Suisse – 10th Annual December Bus Tour

Interactive Tool

With our interactive tool you can analyze and graph a variety of key figures of the Fresenius Group and the business segments on an annual and quarterly basis.

Financial key figures

More information
Mitarbeiter

Sustainability

More information

Alternative Performance Measures

Usage of Alternative Performance Measures


The Fresenius Group uses alternative performance measures in its regulatory and mandatory publications that may represent so called non-GAAP-measures. These indicators are neither defined by US-GAAP nor by IFRS.

Within the internal control system of Fresenius non-GAAP-measures are used as key performance indicators.

The use of non-GAAP-measures for evaluating assets, financial and earnings position of Fresenius is not recommended on an isolated basis or as an alternative to the key performance indicators provided within the consolidated financial statements prepared in accordance with US-GAAP and IFRS.

The non-GAAP-measures used are listed and explained below:

In order to measure the operating performance extending over several periods, key performance measures are “adjusted“ where applicable.
 

Adjustments may arise from acquisitions/divestitures or the adoption of new accounting standards. Reconciliation tables are available within the respective quarterly or annual report and present the composition of adjustments.

EBIT does include depreciation and write-ups on property, plant and equipment.

EBIT is calculated by subtracting cost of sales, selling, general and administrative expenses and research and development expenses from sales.

EBIT margin is calculated as the ratio of EBIT to sales.

EBITDA is calculated from EBIT by adding depreciations recognized in income and deducting write-ups recognized in income, both, on intangible assets as well as property, plant and equipment.

EBITDA margin is calculated as the ratio of EBITDA to sales.

Financial key figure that shows the net balance of incoming and outgoing payments during a reporting period.

Operating cash flow is a financial measure showing cash inflows from operating activities during a period. Operating cash flow is calculated by subtracting non-cash income and adding non-cash expenses to net income.

Cash flow from investing activities is a financial measure opposing payments for the acquisition or purchase of property, plant and equipment and investments versus proceeds from the sale of property, plant and equipment and investments.

Cash flow from financing activities is a financial measure showing how the investments of the reporting period were financed.

Cash flow from financing activities is calculated from additions to equity plus proceeds from the exercise of stock options less dividends paid plus proceeds from debt increase (loans, bonds, senior notes, etc.) less repayments of debt plus the change in noncontrolling interest plus proceeds from the hedge of exchange rate effects due to corporate financing.

Fresenius uses the cash flow before acquisitions and dividends as the financial measure for free cash flow. Cash flow before acquisitions and dividends is calculated by operating cash flow less investments (net). Net investments are calculated by payments for the purchase of property, plant and equipment less proceeds from the sale of property, plant and equipment.

The cash conversion rate is defined as the ratio of adjusted free cash flow (cash flow before acquisitions and dividends; before interest, tax and special items) to operating income (EBIT) before special items. This allows us to assess our ability to generate cash and amongst others, also to pay dividends.

Net debt/EBITDA is a financial measure reflecting the ability of Fresenius to fulfill its payment obligations. Net debt and EBITDA are calculated at LTM (last twelve month) average exchange rates respectively.

Calculation of net debt:
Short-term debt
+ Short-term debt from related parties
+ Current portion of long-term debt and capital lease obligations
+ Current portion of Senior Notes
+ Long-term debt and capital lease obligations, less current portion
+ Senior Notes, less current portion
+ Convertible bonds
= Debt
- less cash and cash equivalents
= Net debt

Indicates the average number of days it takes for a receivable to be paid.

Growth that is generated by a company’s existing businesses and not by acquisitions, divestitures, or foreign exchange impact.

Constant currencies for income and expenses are calculated using prior year average rates; constant currencies for assets and liabilities are calculated using the mid-closing rate on the date of the respective statement of financial position.

Measure of a corporation’s profitability revealing how much profit a company generates
with the money shareholders have invested. ROE is calculated by fiscal year’s net income / total equity x 100.

 

Calculated by: (EBIT - taxes) / Invested capital

Invested capital = total assets + amortization of goodwill (accumulated) - deferred tax assets - cash and cash equivalents - trade accounts payable - accruals (without pension accruals) - other liabilities not bearing interest

 

Reconciliation of average invested capital and ROIC

€ in millions, except for ROIC 31.12.2021 31.12.2020

Total assets

  71,962 66,646

Plus: Cumulative goodwill amortization

719 690

Minus: Cash and cash equivalents

- 2,764 - 1,837

Minus: Loans to related parties

 - 63 - 62

Minus: Deferred tax assets

 -858 -812

Minus: Accounts payable

- 2,039- 1,816

Minus: Accounts payable to related parties

 - 92 - 67

Minus: Provisions and other current liabilities1

 - 8,925 - 8,649

Minus: Income tax payable

 - 495 - 504

Invested Capital

 57,445 53,589

Average invested capital as of December 31, 2021 / 20202

 55,893 54,648

Operating income3,4

 4,260 4,614

Income tax expense

 - 964  - 1,065

NOPAT3,4

 3,296 3,549

ROIC in %

  5.9 % 6.5 %

  • 1 Includes non-current provisions and payments outstanding for acquisition; does not include pension liabilities and noncontrolling interest subject to put provisions.
    2 Includes adjustments for acquisitions in the respective reporting period with a purchase price above a certain level
    (2021: € 752 million; 2020: € 220 million).
    3 Includes adjustments for acquisitions in the respective reporting period with a purchase price above a certain level
    (2021: € 8 million; 2020: € 2 million).
    4 Before special items

Calculated as the ratio of EBIT to operating assets (average).

Operating assets = total assets - deferred tax assets - trade accounts payable - cash held in trust - payments received on account - approved subsidies

 

Reconciliation of average operating assets and ROOA

€ in millions, except for ROOA 31.12.2021 31.12.2020

Total assets

71,962 66,646

Minus: Contract liabilities

 - 535 - 962

Minus: Payments received on account

 0 0

Minus: Cash held in trust

 - 154 - 121

Minus: Loans to related parties

 - 63 - 62

Minus: Deferred tax assets

 - 858 - 812

Minus: Accounts payable

 - 2,039 - 1,816

Minus: Accounts payable to related parties

 - 92 - 67

Minus: Approved subsidies due to Hospital Funding Act („Krankenhausfinanzierungsgesetz“, KHG)

 - 118 - 82

Operating assets

 68,103 62,724

Average operating assets as of December 31, 2021 / 20201

 65,384 62,976

Operating income2,3

 4,260 4,614

ROOA in % 

6.5 % 7.3 %

  • 1 Includes adjustments for acquisitions in the respective reporting period with a purchase price above a certain level
    (2021: € 868 million; 2020: € 346 million).
    2 Includes adjustments for acquisitions in the respective reporting period with a purchase price above a certain level
    (2021: € 8 million; 2020: € 2 million).
    3 Before special items

Indicates the average number of days between receiving goods as inventory and the sale of the finished product.

Calculated by: (Inventories / Costs of goods sold) x 365 days

In order to measure the operating performance extending over several periods, key performance measures are adjusted by special items, where applicable. Adjusted measures are labelled with “before special items”. A reconciliation table is available within the respective quarterly or annual report and presents the composition of special items.

Current assets (including deferred assets) - accruals - trade accounts payable - other liabilities - deferred charges

Hospital Director Sandra Henek (left) and Deputy Ward Manager Regina Ascher say thanks and farewell to Nurse Florence de Peralta (center).

Her first look at Germany on that long-ago morning was not very encouraging. “Everything here looks so gray and dismal,” Florence de Peralta remembers thinking as she landed in Frankfurt back in February 1972. The young nurse was used to the warm temperatures of her native Philippines, not the cold winters of western Europe. But she had taken a decision to pursue a new life, so she got off the plane and started building it.

(Published: August 2015)

Forty-four years later, de Peralta, now 67 and recently retired from HELIOS Hospital Hünfeld, can look back on a successful career at the hospital and the founding and raising of a family in Germany. She’s glad she came, and that she stayed, even if it wasn’t always easy.

When Florence de Peralta arrived along with five other young Philippine nurses assigned to the hospital in Hünfeld, a town of 16,000 people some 100 kilometers (60 miles) north of Frankfurt, Germany was far less multicultural than it is today. The six nurses only came because of an intergovernmental agreement that nurses from the Philippines would work in Germany to help overcome a serious nursing shortage. In total, some 3,000 Philippine nurses came between 1969 and 1973. Thousands of nurses from India and Korea were also recruited during those years.

The HELIOS clinic in Hünfeld

Today, advance preparation – especially language training – is customary for newcomers to Germany, but in Florence de Peralta’s day it wasn’t thought necessary. She arrived not knowing a word of German but was still expected to start right away at the hospital, “where we communicated with hand signals,” and take language lessons later.

She soon got used to her new country, though, with the help of colleagues and many friendly local people, including some families who helped her settle in and find her way around. “I was given a very warm welcome everywhere, both from the people in Hünfeld and from the colleagues and patients in the hospital,” Florence de Peralta recalls.

Still, Hünfeld is a small town, de Peralta was away from family and friends and living in a country with a very different culture. At times, homesickness was hard to shake. Then, at a gathering of the German-Philippine Association in Mainz, just west of Frankfurt, she bumped into Arsenio, whom she had known before taking her training back home. “He wouldn’t let me go,” she jokes of the man who would become her husband and with whom she has two children, Florian and Jennifer. She and Arsenio even worked together for a time in the Hünfeld hospital.

 

Florence de Peralta enters retirement with mixed feelings – sorry to say goodbye to work that has given her so much satisfaction, but grateful for the memories, the friends and colleagues, not to mention the many happy years of family life. “Nursing has brought me a lot of pleasure and joy,” Florence de Peralta says. “Having some understanding and sympathy for ill people and looking after them – that has always been my passion.” And for Florence and Arsenio de Peralta, there is still a lot to look forward to – including a long trip back to the country they left behind all those years ago for their new home in Germany.

Without the successful surgery by the medical team at HELIOS Hospital Hildesheim, life might have taken a hard turn for Frauke Quidde. She was cutting firewood on her small farm last year when her hand slipped inside a log-splitting machine and was almost completely severed at the wrist. “It was a total, absolute shock,” she recalled. “My right hand was literally hanging by threads.”

(Published: January 2016)

Every minute counted now. While waiting for emergency personnel to arrive at the farm near Braunschweig – a northern German city also known as Brunswick – Frauke Quidde had to use her left hand to hold the severed hand in place as best she could. Then she was moved into a rescue helicopter, which flew her approximately 45 kilometers (28 miles) to HELIOS Hospital Hildesheim, where a surgical team headed by Dr. Bernd Rieck was standing ready in the operating room.

“It was crucial to restore the blood flow as quickly as possible,” explained Dr. Rieck, Chief Physician in the hospital’s Plastic, Aesthetic and Hand Surgery Department. “Every quarter hour increases the risk of permanent damage to the hand. So we not only needed to work very precisely, but also very quickly.”

“I was very lucky, but for me it was really a medical masterpiece.” 

Dr. Rieck, Resident Physician Jakob Krainski and the rest of the team decided to rejoin the blood vessels, tendons and nerves before stabilizing the bone – a reversal of the usual order. By the time blood started recirculating through the hand, “only” three hours had elapsed. “That is a phenomenally good time,” Dr. Rieck explained. “You had an old veteran like me and a young master working together at the operating table. This operation had already been performed at other hospitals, but they didn’t all do it as well. It was real teamwork.”

Just two days after the accident, Frauke Quidde could start moving her fingers, and she continued to make rapid progress during rehabilitation. Today, she is back working on the farm, doing all the things she did before: harvesting fruit, driving the tractor, and feeding the animals.

Frauke Quidde and husband Detlev, flanked by Chief Physician Dr. Bernd Rieck (left) and Resident Physician Jakob Krainsk.

“Ms. Quidde is an extraordinarily brave and determined woman,” said Jakob Krainski. “The excellent result is also attributable to her positive approach: She really supported all the therapies and gave tremendous cooperation. I’m really proud of my patient, and she should feel proud, too.”

What Frauke Quidde mostly feels, though, are a sense of gratitude and a deep appreciation that she has been able to return to her old, active life. “I’m really thankful to the doctors, the nurses and the rest of the staff in Hildesheim that I can move my hand again and drive a car, and above all that I can lead an independent life,” she said. “That’s why it was clear to me that the first card I could write from the rehabilitation clinic would be to the medical team in Hildesheim. It was just a small ‘thank you’ to the doctors and the medical staff in the hospital. I was very lucky, but for me it was really a medical masterpiece. My husband and I are unbelievably grateful.”

Fresenius is a global healthcare company headquartered in Bad Homburg v. d. Höhe, Germany. In the 2025 fiscal year, Fresenius generated €22.6 billion in annual revenue. Fresenius currently counts over 178,000 employees. As a healthcare company focused on therapy, Fresenius offers system-critical products and services for leading therapies for the care of critically and chronically ill patients.

The Fresenius Group comprises the Operating Companies Fresenius Kabi and Fresenius Helios as well as the Investment Company Fresenius Medical Care.

We save and improve human lives with affordable, accessible, and innovative healthcare products and the highest quality in clinical care.

View through the camera: Cinderella Glücklich during the shooting for the video interview

A staircase, but no elevator; a high shelf or a very heavy door: Routine, minor annoyances that most people hardly notice, but potentially insurmountable problems for someone in a wheelchair. Office life constantly throws up obstacles like these, so maybe the disabled should forget about working in “ordinary” companies and limit themselves to workshops for the handicapped or similar institutions?

(Published: July 2015)

“No,” Cinderella Glücklich replies, clearly and without hesitation. Yes, she has been disabled since birth and has to spend most of the day in a wheelchair, but she is not going to let that stop her from pursuing her dream of a career in public relations or marketing.

Glücklich has been studying Journalism and Corporate Communications since 2013 in Iserlohn, Germany, and, here at Fresenius, completed an internship in Corporate Communications and Human Resources Marketing. She told us a little bit about some of the difficulties she faces in daily life and, in particular, in searching for a job.

As a disabled person, what is it like searching for a job?
Searching for a job is very difficult for me. There are a lot of bureaucratic obstacles that make it hard for handicapped people to find a job. The barriers in people’s minds are a much bigger problem, though. Many employers refused to hire me because they thought that due to my disability I wouldn’t be able to work. But it’s not like that at all: Working is very important to me, because I want to be independent.

Cinderella Glücklich blogs about her life and the challenges she faces. Cinderella wants to break down prejudices and encourage other disabled people.

Did you decide at a very young age which career you wanted to pursue?
No, after finishing school, at first I looked for some vocational training. But at the government employment center they only wanted to send me to a training center for the severely handicapped. It seemed like an endless search, but in the end I got a year-long internship in a tourist information office. I really enjoyed that, and it enabled me to complete the work experience requirement for the diploma I needed to attend a technical university. After that, it turned out to be almost as difficult to find the right technical university with wheelchair accessibility. But I am happy in Iserlohn.

Your blog about living with a disability. What is your motivation?
In my blog I report first-hand about my life with a disability. I want to break down prejudices. It is very important that people lose their fear of contact with the disabled and the whole issue of disabilities. And it makes me very happy to encourage other disabled people to live their lives in their own way and to live up to their potential.

Why did you decide to do your internship at Fresenius?
I decided to do my internship at Fresenius because I liked that the company helps sick people. And I was completely won over by the uncomplicated way everyone handled my disability, right from the start. They see me as a regular colleague, not just as “the girl in the wheelchair” – and that feels great!

“The barriers in people’s minds are the worst”

Cinderella Glücklich has been handicapped since birth. In an interview, the Fresenius intern talked about the challenges she faces in daily life and in finding a job.

Related Links

Group Overview

Contact

Fresenius SE & Co. KGaA
Else-Kröner-Str. 1
61352 Bad Homburg
Germany
T: +49 6172 608-0
pr-fre@fresenius.com

Fresenius delivers an excellent quarter and is scaling its Growth Vectors - Core EPS guidance improved

In Q3/26, Fresenius continued to build on the structural improvements from its #FutureFresenius transformation, delivering healthy organic revenue growth, double-digit Core EPS growth while further improving returns. The company’s Growth Vectors continued to gain share, while the hospital business sustained resilient growth. Based on the upgraded core and the increased strategic flexibility, Fresenius started to scale its Biopharma business through targeted investments.

 

  • Group revenue1 at €5,803 million with organic growth of 5%1,2 driven by both Fresenius Kabi and Fresenius Helios.  
  • Group EBIT1 at €638 million with 10% growth in constant currency driven by Fresenius Kabi’s Growth Vectors, and Fresenius Helios’ excellent EBIT growth despite the usual seasonality in the hospital business; Group EBIT margin1 expansion by 50 bps to 11.0%. 
  • Core EPS1,3 growth at 14% in constant currency to €0.72 largely driven by strong operating performance and further reduction of interest expense, reflecting the benefits of continued debt reduction. 
  • Group FY/26 guidance on Core EPS growth improved: now expected at the upper half of the 10% to 15% range in constant currency. 
  • Group EBIT margin indication raised: now expected above 11.5% (before around 11.5%) 
  • ROIC at 7.0%, moving up within the Fresenius Financial Framework ambition range of 6% to 8% reaching its highest level of the decade. 
  • Net debt/EBITDA ratio at 2.5x1,4, including about 20bps impact related to mAbxience transaction.

 

1 Before special items
2 Organic growth rate adjusted for accounting effects related to Argentina hyperinflation
3 Excluding Fresenius Medical Care and Vitrea
4 At average exchange rates for both net debt and EBITDA; pro forma closed acquisitions/divestitures, including lease liabilities, including dividends from Fresenius Medical Care and Vitrea, net debt adjusted for the valuation effect of the exchangeable bond

 

Selected Key Figures Q3/2026

GROUP REVENUE 1

€ 5803 m

+5% 2

Q3/25: €5,477 m

GROUP EBIT 1

€ 638 m

+10% 4

Q3/25: €574 m

CORE NET INCOME 1, 3

€ 403 m

+14% 4

Q3/25: €351 m

CORE EPS 1, 3

€ 0.72

+14% 4

Q3/25: €0.62

1 Before special items

2 Organic growth rate adjusted for accounting effects related to Argentina hyperinflation

3 Excluding Fresenius Medical Care and Vitrea

4 Constant currency growth

Revenue by business segment

€ in millions Q3/26 Q3/25 Growth at actual ratesGrowth at constant rates1Organic growth1Acquisitions/Divestitures% of total revenue

Fresenius Kabi

2,3042,1418%5%6%-1%40%

Fresenius Helios

3,4053,2405%4%5%-1%59%

Total

5,8035,4776%4%5%-1%100%2

  • 1 Growth rate adjusted for accounting effects related to Argentina hyperinflation

    2 Remaining 2% Corporate/Other revenue

    Before special items

Archive

Investor Portal of Fresenius SE & Co. KGaA

Following the transition to registered shares, the Investor Portal is available to Shareholders throughout the year.

Ahead of the Annual General Meeting, Shareholders can use the Investor Portal to exercise their voting right by electronic postal ballot, authorize third parties or authorize and instruct the proxies nominated by the Company.

Access details for the Investor Portal will be provided to Shareholders by email or post.

If you have any questions, please feel free to contact us via our e-mail address at ir-fre@fresenius.com.

The Annual General Meeting of Fresenius SE & Co. KGaA took place on May 22, 2026, at the Congress Center, Messe Frankfurt, Ludwig-Erhard-Anlage 1, 60327 Frankfurt am Main, Germany.

Internet broadcast

 

The opening of the Annual General Meeting by the Chairman of the Supervisory Board, Wolfgang Kirsch, and the report by the Chairman of the Management Board, Michael Sen, were broadcast publicly. 

Information on the Annual General Meeting on May 22, 2026

Invitation / Agenda

Information for shareholders

Information on the Agenda items

Additional Information

Further publications

Countermotions and election proposals

Below, you find the countermotions from a shareholder within the meaning of section 126 of the German Stock Corporation Act (Aktiengesetz) on items 3 and 4 of the agenda of the Annual General Meeting of Fresenius SE & Co. KGaA on May 22, 2026.

Total number of shares and of voting rights at the time of the convocation (Section 124 a sentence 1 no. 4 of the German Stock Corporation Act)

At the time the General Meeting is convened, 563,237,277 ordinary shares out of a total of 563,237,277 ordinary shares issued carry rights of participation and voting rights.

 

 

Archive

The Annual General Meeting of Fresenius SE & Co. KGaA took place on May 23, 2025, at the Congress Center, Messe Frankfurt, Ludwig-Erhard-Anlage 1, 60327 Frankfurt am Main, Germany.

Chairman Letter Wolfgang Kirsch

Countermotions and election proposals

Below, you find the countermotions from a shareholder within the meaning of section 126 of the German Stock Corporation Act (Aktiengesetz) on items 3 and 10 of the agenda of the Annual General Meeting of Fresenius SE & Co. KGaA on May 23, 2025.

Total number of shares and of voting rights at the time of the convocation (Section 124 a sentence 1 no. 4 of the German Stock Corporation Act)

At the time the General Meeting is convened, 563,237,277 ordinary shares out of a total of 563,237,277 ordinary shares issued carry rights of participation and voting rights.

The Annual General Meeting of Fresenius SE & Co. KGaA  took place on Friday, 17 May 2024 at the Congress Center, Messe Frankfurt, Ludwig-Erhard-Anlage 1, 60327 Frankfurt am Main, Germany.

Chairman Letter Wolfgang Kirsch

Countermotions

Currently, there are no countermotions.

 
Total number of shares and of voting rights at the time of the convocation (Section 124 a sentence 1 no. 4 of the German Stock Corporation Act)

At the time the General Meeting is convened, 563,237,277 ordinary shares out of a total of 563,237,277 ordinary shares issued carry rights of participation and voting rights.

The virtual Annual General Meeting of Fresenius SE & Co. KGaA took place on May 17, 2023.

Invitation / Agenda

Information for shareholders

Information on the agenda items

Additional Information

Further publications

Countermotions

Currently, there are no countermotions.

 
Total number of shares and of voting rights at the time of the convocation (Section 124 a sentence 1 no. 4 of the German Stock Corporation Act)

At the time the General Meeting is convened, 563,237,277 ordinary shares out of a total of 563,237,277 ordinary shares issued carry rights of participation and voting rights.

The virtual Annual General Meeting 2022 of Fresenius SE & Co. KGaA took place on May 13, 2022.

Invitation / Agenda

Information for shareholders

Information on scrip dividend

Information on the agenda item

Additional Information

Further publications

Countermotions and election proposals

Below, you find the countermotion from a shareholder within the meaning of section 126 of the German Stock Corporation Act (Aktiengesetz) on item 3 of the agenda of the virtual Annual General Meeting of Fresenius SE & Co. KGaA on May 13, 2022 as well as the statement of the management.

Total number of shares and of voting rights at the time of the convocation (Section 124 a sentence 1 no. 4 of the German Stock Corporation Act)

At the time the General Meeting is convened, 558,502,143 ordinary shares out of a total of 558,502,143 ordinary shares issued carry rights of participation and voting rights.

 

The virtual Annual General Meeting 2021 of Fresenius SE & Co. KGaA took place on May 21, 2021.

Invitation/Agenda

Information for shareholders

Information on the agenda items

Additional Information

Countermotions, election proposals, statement of the Management

Counter motions

No counter motions were received.

 

Total number of shares and of voting rights at the time of the convocation (Section 124 a sentence 1 no. 4 of the German Stock Corporation Act)

At the time the General Meeting is convened, 557,543,909 ordinary shares out of a total of 557,543,909 ordinary shares issued carry rights of participation and voting rights.

The virtual Annual General Meeting 2020 of Fresenius SE & Co. KGaA took place on August 28, 2020.

Counter motions

No counter motions were received.

 

Total number of shares and of voting rights at the time of the convocation (Section 124 a sentence 1 no. 4 of the German Stock Corporation Act)

At the time the General Meeting is convened, 557,467,084 ordinary shares out of a total of 557,467,084 ordinary shares issued carry rights of participation and voting rights.

The Annual General Meeting 2019 of Fresenius SE & Co. KGaA took place on Friday, May 17, 2019, at the Congress Center Messe Frankfurt, Ludwig-Erhard-Anlage 1, 60327 Frankfurt am Main.

Counter motions

No counter motions were received.

 

Total number of shares and of voting rights at the time of the convocation (Section 124 a sentence 1 no. 4 of the German Stock Corporation Act)

At the time the General Meeting is convened, 556,323,366 ordinary shares out of a total of 556,323,366 ordinary shares issued carry rights of participation and voting rights.

The Annual General Meeting 2018 of Fresenius SE & Co. KGaA took place on Friday, May 18, 2018, at the Congress Center Messe Frankfurt, Ludwig-Erhard-Anlage 1, 60327 Frankfurt am Main.

Further information on the AGM 2018

Counter motions

No counter motions were received.

Total number of shares and of voting rights at the time of the convocation (Section 124 a sentence 1 no. 4 of the German Stock Corporation Act)

At the time the General Meeting is convened, 554,875,179 ordinary shares out of a total of 554,875,179 ordinary shares issued carry rights of participation and voting rights.

The Annual General Meeting 2017 of Fresenius SE & Co. KGaA took place on Friday, May 12, 2017, at the Congress Center Messe Frankfurt, Ludwig-Erhard-Anlage 1, 60327 Frankfurt am Main.

Further information on the AGM 2017

Counter motions

No counter motions were received.
 

Total number of shares and of voting rights at the time of the convocation (Section 124 a sentence 1 no. 4 of the German Stock Corporation Act)

At the time the General Meeting was convened, 553,489,493 ordinary shares out of a total of 553,489,493 ordinary shares issued carried rights of participation and voting rights.

The Annual General Meeting 2016 took place on Friday May 13, 2016 at the Congress Center Messe Frankfurt, Ludwig-Erhard-Anlage 1, 60327 Frankfurt, Germany.

Webcast of the speech of the CEO Dr. Ulf M. Schneider

Further information on the AGM 2016

Counter motions
No counter motions were received.

The Annual General Meeting 2015 took place on Wednesday May 20, 2015 at the Congress Center Messe Frankfurt, Ludwig-Erhard-Anlage 1, 60327 Frankfurt, Germany. 

Further information on the AGM 2015

Counter motions
No counter motions were received.

 

Section 124 a sentence 1 no. 4 of the German Stock Corporation Act: the total number of shares and of voting rights at the time of the convocation:

At the time the General Meeting was convened, 542,820,402 ordinary shares out of a total of 542,820,402 ordinary shares issued carried rights of participation and voting rights.

The Annual General Meeting 2014 took place on Friday May 16, 2014 at the Congress Center Messe Frankfurt, Ludwig-Erhard-Anlage 1, 60327 Frankfurt, Germany. 

Counter motions
No counter motions were received.

 

Section 124 a sentence 1 no. 4 of the German Stock Corporation Act: the total number of shares and of voting rights at the time of the convocation:

At the time the General Meeting was convened, 179,824,079 ordinary shares out of a total of 179,824,079 ordinary shares issued carried rights of participation and voting rights.

The Annual General Meeting 2013 took place on Friday May 17, 2013 at the Congress Center Messe Frankfurt, Ludwig-Erhard-Anlage 1, 60327 Frankfurt, Germany. 

Counter motions

No counter motions were received.

Section 124 a sentence 1 no. 4 of the German Stock Corporation Act: the total number of shares and of voting rights at the time of the convocation:

At the time the General Meeting is convened, 178,277,853 ordinary shares out of a total of 178,277,853 ordinary shares issued carry rights of participation and voting rights.

The Annual General Meeting 2012 took place on Friday May 11, 2012 at the Congress Center Messe Frankfurt, Ludwig-Erhard-Anlage 1, 60327 Frankfurt, Germany. 

Counter motions

No counter motions received

Section 124 a sentence 1 no. 4 of the German Stock Corporation Act: the total number of shares and of voting rights at the time of the convocation

At the time the General Meeting was convened, 163,334,670 ordinary shares out of a total of 163,334,670 ordinary shares issued carried rights of participation and voting rights.

The Annual General Meeting 2011 took place on Friday May 13, 2011, at the Congress Center Messe Frankfurt, Ludwig-Erhard-Anlage 1, 60327 Frankfurt, Germany. 

Counter motions
No counter motions were received

 

Section 124 a sentence 1 no. 4 of the German Stock Corporation Act: the total number of shares and of voting rights at the time of the convocation

At the time the General Meeting was convened, 162,450,090 ordinary shares out of a total of 162,450,090 ordinary shares issued carried rights of participation and voting rights.

The Annual General Meeting 2010 took place on Wednesday May 12, 2010 at the Congress Center Messe Frankfurt, Ludwig-Erhard-Anlage 1, 60327 Frankfurt, Germany. 

Information on the agenda items

The Annual General Meeting 2009 took place on Friday May 8, 2009 at the Congress Center Messe Frankfurt, Ludwig-Erhard-Anlage 1, 60327 Frankfurt, Germany. 

The Annual General Meeting 2008 took place on Wednesday May 21, 2008 at the Congress Center Messe Frankfurt, Ludwig-Erhard-Anlage 1, 60327 Frankfurt, Germany. 

Worldwide

Fresenius Helios

Europe

Largest European hospital operator

Fresenius Helios is Europe's leading private health care provider, with 127,000 employees. Together with Quirónsalud in Spain and Latin America, the Helios Group in Germany is part of the Helios Health holding. Every year about 26 million patients choose Helios for their medical treatment. In 2023, the company’s sales totaled more than €12 billion.Helios Germany operates more than 80 hospitals, about 230 outpatient care centers with 600 accredited doctor's licenses, six prevention centers and 27 occupational medicine centers. Helios treats approximately 5.5 million patients annually, of whom 4 million are outpatients. Since its beginnings, Helios has focused on measurable, high medical quality as well as data transparency and is better than the German average in 89 per cent of the quality targets. With more than 78,000 employees, Helios generated sales of €7.3 billion in 2023. Helios Germany is headquartered in Berlin.Quirónsalud operates 57 hospitals, including seven in Latin America, 100 outpatient centers and around 300 occupational risk prevention centers, and treats approximately 20 million patients annually, of whom 19 million are outpatients. Quirónsalud has more than 49,000 employees and generated sales of €4.8 billion in 2023.Helios is part of the Fresenius healthcare group.

Contact

Helios Kliniken GmbH
Friedrichstr. 136
10117 Berlin
Germany
T +49 30 521 321-0

www.helios-gesundheit.de

Contact

Grupo Hospitalario Quirónsalud
C\ Zurbarán 28
28010 Madrid
Spain

www.quironsalud.es

Video

A Hospital is Restored to Health

Being acquired by Helios is bringing the Krefeld municipal hospital back on track.

Fresenius

Europe

Corporate Headquarters

The Fresenius corporate head office is located in Bad Homburg. Fresenius SE & Co. KGaA and the Fresenius Medical Care and Fresenius Kabi business segments have their main offices here.

Contact

Fresenius SE & Co. KGaA
Else-Kröner-Str. 1
61352 Bad Homburg
Germany
T: +49 6172 608-0
pr-fre@fresenius.com

Fresenius

Asia-Pacific

Successful in China for more than 30 years

China has played a major role in the development of Fresenius. The health care group was already active in “The Middle Kingdom” in the early 1980s, and has been gaining experience and know-how in this key market ever since. Fresenius Kabi now operates four plants in China. It is the market leader in parenteral nutrition, a leading supplier of infusion therapies, and one of the largest foreign-based pharmaceutical companies in the country. Fresenius Vamed has also successfully completed numerous projects in China. Among them: Equipping a number of hospitals with the latest medical technology, and erecting the 680-bed First People’s Hospital in Shanghai on a turnkey basis.

Contact

Fresenius Kabi (China) Co. Limited
16F, GrandyVic Building, No.16, Taiyanggong Mid Street
Chaoyang District
1000028 Beijing, China
T +86 10 5909 6999

www.fresenius-kabi.com/cn

Contact

Fresenius Medical Care (Shanghai) Co. Ltd.
Unit 4601-05&11, 46F, 2 Grand Gateway
3 Hongqiao Road, Xu Hui District
200030 Shanghai, China
T +86 21 6115 2800

Fresenius Helios

Europe

Using protons to take on cancer

One of the most advanced cancer treatments, proton beam therapy works by radiating the tumor with positively charged hydrogen atoms, and has major advantages over traditional radiation therapy. In 2020, Quirónsalud, the Spanish hospital group of Fresenius Helios,  has opened that country’s first proton beam therapy center.Quirónsalud has opted for the Proteus One, a unique proton beam therapy system which, unlike others systems, allows all the technology necessary for treatment to be grouped together in one multifunctional room. It includes a tumor-scanning system to help doctors determine the optimal dose for each part of the body being treated, as well as a state-of-the-art imaging systems. And Proteus One can rotate 360 degrees, to direct the beam from any desired angle.

Contact

Grupo Hospitalario Quirónsalud
C\ Zurbarán 28
28010 Madrid
Spain

www.quironsalud.es

Video

Spain’s first proton beam therapy center

Quirónsalud is on the leading-edge of cancer care building the first Protont Therapy Center in Spain

Fresenius Kabi

Europe

State of the art production of infusions

In Friedberg, Germany, Fresenius Kabi operates a state of the art production facility for infusion solutions. The plant employs about 1,000 people. The company delivers infusion solutions in plastic bags or bottles from Friedberg to pharma wholesalers, pharmacists and hospitals. Every day, the employees of the Friedberg Logistics Center send out around 2,000 orders with the aid of modern software and a fully-automated high-rack warehouse to customers all over the world.

Contact

Fresenius Kabi Deutschland GmbH
Werk Friedberg
Freseniusstr. 1
61169 Friedberg
Germany
T: +49 (0) 6172 686-0

Fresenius

Latin America

Major player in Latin America

Fresenius has been active in Brazil longer than in any other country outside of Europe, having set up its own distributor there in the mid-1970s. The acquisition of Hiplex, a pharmaceutical company specializing in infusion solutions and based in Campinas, Sao Paulo state, followed in 1977. Brazil continues to play a leading role in Fresenius’ Latin American activities. Fresenius Kabi and Fresenius Medical Care both have their own plants in the country, and Fresenius Medical Care also operates dialysis clinics. In total, Fresenius employs around 4,000 people in Brazil.

Contact

Fresenius Kabi Brasil Ltda.
Av. Marginal Projetada, 1652 - G1
06464-200 Tamboré - Barueri - São Paulo
Brazil
T +55 11 2504 1400

www.fresenius-kabi.com/br
Stories   |  

Archive

Video message from Michael Sen
Image
Michael Sen

Europe

Video message from Michael Sen

Our new CEO outlines what will be essential for #FutureFresenius.

Doubling up on a second chance
Image
Herzen_Bühnenbild

Europe

Doubling up on a second chance

Twin brothers Kilian and Jamie both suffered from a heart weakness. Just three days apart, they each received a transplanted heart at Fresenius Helios.

Midwife, a dream job
Image
baby

Europe

Midwife, a dream job

After her son was born, Lea Zerbe decided to become a midwife and enrolled in a training program at Helios Mariahilf Hospital in Hamburg

In battle against the coronavirus
Image
Helios_Schwelm_Coron

Worldwide

In battle against the coronavirus

Fresenius is taking comprehensive measures to ensure healthcare is available for patients during the COVID-19 pandemic.

Paul, the four-legged therapist
Image
Paul_1

Europe

Paul, the four-legged therapist

Loyal and sympathetic eyes, soft fur and a wet nose: Paul the therapy dog is the first animal employee of the Fresenius Helios hospital in the northern German city of Hildesheim.

Using protons to take on cancer
Image
Protonentherapie_Madrid

Europe

Using protons to take on cancer

Fresenius Helios to open Spain’s first proton beam therapy center.

Ready to help the littlest ones
Image
Neonatologie_Schwerin

Europe

Ready to help the littlest ones

Some children have to fight for life, right from birth: A day on the Neonatology ward of HELIOS Hospital Schwerin, Germany.

A little heart at the center of a complex surgery
Image
Herzzentrum_Leipzig_OP_Kostelka

Europe

A little heart at the center of a complex surgery

For more than 20 years, Fresenius Helios’ Leipzig Heart Center has been providing highest quality cardiac care – sometimes to very young patients.

’Remain true to your ideals’
Image
GK80

Europe

’Remain true to your ideals’

On the occasion of his 80th birthday, the Supervisory Board Chairman of Fresenius, Dr. Gerd Krick, agreed to sit down and take some questions from two young colleagues.

Making mistakes to avoid them
Image
Simzentrum_Hals

Europe

Making mistakes to avoid them

Simulating the symptoms of patients in crisis, life-like mannequins help create a high-pressure but highly valuable training opportunity for doctors and nurses at Fresenius Helios.

Crucial lessons learned
Image
Helios_Duisburg

Europe

Crucial lessons learned

Faced with one of the ‘superbugs’ that pose a huge health threat worldwide, Fresenius Helios turned to advanced hygiene management.

Dialysis patient succeeds in giving birth
Image
Dialysebaby_Mutter_mit_Baby

Europe

Dialysis patient succeeds in giving birth

It is extremely rare for a dialysis patient to give birth, but Jaqueline Sinicyn refused to be deterred by the long odds. Now, she has a beautiful baby.

Returning a hospital to health in Germany
Image
Krefeld

Europe

Returning a hospital to health in Germany

Once municipally owned and deeply in debt, the facility is now thriving as part of Fresenius Helios.

24 hours on the Intensive Care Unit
Image
Intensive

Europe

24 hours on the Intensive Care Unit

Round the clock dedication of ICU doctors and nurses can be seen at HELIOS hospital near Berlin.

From the Philippines to Germany was only the start
Image
HELIOS-Nurse

Europe

From the Philippines to Germany was only the start

1972, with Germany beset by a serious shortage of nurses, Florence de Peralta reported to what is now HELIOS Hospital Hünfeld.

Surgeons save woman’s hand after accident on farm
Image
Hand_ab_Traktor_ohne_Nummernschild

Europe

Surgeons save woman’s hand after accident on farm

Extreme precision under intense time pressure was essential, and is precisely what surgeons at a HELIOS hospital achieved for the benefit of a woman in serious danger of losing her hand.

“The barriers in people’s minds are the worst”
Image
Cinderella_Gluecklich

Europe

“The barriers in people’s minds are the worst”

Cinderella Glücklich has been handicapped since birth. In an interview, the Fresenius intern talked about the challenges she faces in daily life and in finding a job.

Subscribe to